Table 2 Treatment characteristics in ICU patients
From: Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome
Treatment | Survivors (N = 16) | Non-survivors (N = 12) | P value |
|---|---|---|---|
Tocilizumab N(%) | 4 (25) | 4 (25) | 0.6908 |
Remdesivir N(%) | 3 (18.8) | 4 (5) | 0.6618 |
Hydroxychloroquine N(%) | 12 (75) | 12 (100) | 0.1131 |
Ritonavir/Lopinavir N(%)a | 7 (50) | 9 (75) | 0.1358 |
Corticosteroids N(%)b | |||
- Dexamethasone 0.4 mg·Kg− 1 | 4 (25) | 5(42) | 0.4319 |
- Methylprednisolone 0.3 mg·Kg−1 | 0 (0) | 1(8.3) | 0.4286 |
- Hydrocortisone 150 mg·die−1 | 1 (6.25) | 1(8.3) | > 0.999 |
Mechanical ventilationc | |||
- Vt/IBW -ml Kg−1d | 7.85(7.6–8.85) | 6.4 (6.1–8) | 0.4275 |
- PEEP -cmH20 | 11(8–13.25) | 12 (8–12) | 0.9073 |